Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20264266 | 0.91 | NPC1 (0.44) | NPC1SRCUSP2ALDH1A1TSHR | |
| SCHEMBL20264358 | 0.89 | NPC1 (0.45) | NPC1SRCTP53MAPTSMN1; SMN2 | |
| SCHEMBL26961716 | 0.89 | NPC1 (0.46) | NPC1SRCTP53MAPTSMN1; SMN2 | |
| SCHEMBL20264309 | 0.88 | TP53 (0.51) | NPC1SRCTP53MAPTSMN1; SMN2 | |
| SCHEMBL20286532 | 0.87 | NPC1 (0.45) | NPC1TP53MAPTSMN1; SMN2LMNA | |
| SCHEMBL20263859 | 0.86 | NPC1 (0.42) | NPC1USP2ALDH1A1TSHRNPSR1 | |
| SCHEMBL29796955 | 0.86 | NPC1 (0.45) | NPC1TP53MAPTSMN1; SMN2LMNA | |
| SCHEMBL20264153 | 0.86 | NPC1 (0.45) | NPC1TP53MAPTSMN1; SMN2LMNA | |
| SCHEMBL20264277 | 0.86 | TP53 (0.45) | NPC1SRCTP53MAPTSMN1; SMN2 | |
| SCHEMBL20264063 | 0.85 | MAPT (0.46) | NPC1TP53MAPTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472341-B2 | Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases | APEIRON BIOLOGICS AG (AT) | 2019-11-12 | — | — | US | disclosed |
| US-10472341-B2 | Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases | APEIRON BIOLOGICS AG (AT) | 2019-11-12 | — | — | US | disclosed |
| EP-3265463-B1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES | APEIRON BIOLOGICS AG (AT) | 2018-12-19 | — | — | EP | disclosed |
| US-20180170888-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES | APEIRON BIOLOGICS GMBH (AT) | 2018-06-21 | — | — | US | disclosed |
| US-20180170888-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES | APEIRON BIOLOGICS GMBH (AT) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472341-B2 | Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases | CCNT2, HRH4, HRH3 | NPC1 563/4885SRC 3256/4885USP2 4756/4885 |
| US-20180170888-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES | CCNT2, HRH4, HRH3 | NPC1 563/4885SRC 3256/4885USP2 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.